260 related articles for article (PubMed ID: 24463935)
1. Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats.
Lee TM; Chung TH; Lin SZ; Chang NC
J Hypertens; 2014 Apr; 32(4):795-805. PubMed ID: 24463935
[TBL] [Abstract][Full Text] [Related]
2. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
Carneiro FS; Nunes KP; Giachini FR; Lima VV; Carneiro ZN; Nogueira EF; Leite R; Ergul A; Rainey WE; Clinton Webb R; Tostes RC
J Sex Med; 2008 Dec; 5(12):2793-807. PubMed ID: 18823320
[TBL] [Abstract][Full Text] [Related]
3. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
Matsumura Y; Hashimoto N; Taira S; Kuro T; Kitano R; Ohkita M; Opgenorth TJ; Takaoka M
Hypertension; 1999 Feb; 33(2):759-65. PubMed ID: 10024341
[TBL] [Abstract][Full Text] [Related]
4. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
5. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
Ndisang JF; Jadhav A
J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
[TBL] [Abstract][Full Text] [Related]
6. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
7. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
Li L; Watts SW; Banes AK; Galligan JJ; Fink GD; Chen AF
Hypertension; 2003 Sep; 42(3):316-21. PubMed ID: 12885792
[TBL] [Abstract][Full Text] [Related]
8. Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
Kimura K; Ohkita M; Koyama M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):644-50. PubMed ID: 22569294
[TBL] [Abstract][Full Text] [Related]
9. Selective antagonism of endothelin ET(A) or ET(B) receptor in renal hemodynamics and function of deoxycorticosterone acetate-salt-induced hypertensive rats.
Matsumura Y; Taira S; Kitano R; Hashimoto N; Kuro T
Biol Pharm Bull; 1999 Aug; 22(8):858-62. PubMed ID: 10480326
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the endothelin ET(B) receptor in gender differences in deoxycorticosterone acetate-salt-induced hypertension.
Kawanishi H; Hasegawa Y; Nakano D; Ohkita M; Takaoka M; Ohno Y; Matsumura Y
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):280-5. PubMed ID: 17324138
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Hypertens Res; 2010 Mar; 33(3):255-62. PubMed ID: 20057489
[TBL] [Abstract][Full Text] [Related]
13. Cardiac sympathetic hyperinnervation in deoxycorticosterone acetate-salt hypertensive rats.
Lee TM; Chen CC; Chang NC
Clin Sci (Lond); 2012 Oct; 123(7):445-57. PubMed ID: 22507072
[TBL] [Abstract][Full Text] [Related]
14. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension.
Gómez-Guzmán M; Jiménez R; Sánchez M; Zarzuelo MJ; Galindo P; Quintela AM; López-Sepúlveda R; Romero M; Tamargo J; Vargas F; Pérez-Vizcaíno F; Duarte J
Free Radic Biol Med; 2012 Jan; 52(1):70-9. PubMed ID: 22001745
[TBL] [Abstract][Full Text] [Related]
15. Effect of an ET(B)-selective and a mixed ET(A/B) endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension.
Johnson RJ; Galligan JJ; Fink GD
J Hypertens; 2001 Mar; 19(3):431-40. PubMed ID: 11288813
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
Xia CF; Bledsoe G; Chao L; Chao J
Am J Physiol Renal Physiol; 2005 Sep; 289(3):F622-31. PubMed ID: 15886273
[TBL] [Abstract][Full Text] [Related]
17. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats.
Ishikawa Y; Nishikimi T; Akimoto K; Ishimura K; Ono H; Matsuoka H
Hypertension; 2006 Jun; 47(6):1075-83. PubMed ID: 16636194
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
Larivière R; Sventek P; Thibault G; Schiffrin EL
Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
[TBL] [Abstract][Full Text] [Related]
20. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats.
Callera GE; Montezano AC; Touyz RM; Zorn TM; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
Hypertension; 2004 Apr; 43(4):872-9. PubMed ID: 14993193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
